Suresh Mahalingam Selected Research

bindarit

3/2017	Targeting the pro-inflammatory factor CCL2 (MCP-1) with Bindarit for influenza A (H7N9) treatment.
12/2015	Correction for Chen et al., Bindarit, an Inhibitor of Monocyte Chemotactic Protein Synthesis, Protects against Bone Loss Induced by Chikungunya Virus Infection.
1/2015	Bindarit, an inhibitor of monocyte chemotactic protein synthesis, protects against bone loss induced by chikungunya virus infection.
10/2011	Protection from arthritis and myositis in a mouse model of acute chikungunya virus disease by bindarit, an inhibitor of monocyte chemotactic protein-1 synthesis.
8/2009	Amelioration of alphavirus-induced arthritis and myositis in a mouse model by treatment with bindarit, an inhibitor of monocyte chemotactic proteins.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Suresh Mahalingam Research Topics

Disease

25	Infections 01/2022 - 02/2006
15	Arthritis (Polyarthritis) 01/2022 - 01/2007
11	Myositis (Idiopathic Inflammatory Myopathies) 01/2022 - 05/2007
10	Inflammation (Inflammations) 01/2022 - 10/2006
7	Virus Diseases (Viral Diseases) 06/2019 - 07/2008
5	Rheumatoid Arthritis 01/2022 - 07/2011
4	Alphavirus Infections 01/2019 - 10/2013
4	Chikungunya Fever 01/2017 - 11/2013
3	Ross River Virus Infection 01/2022 - 11/2014
3	Joint Diseases (Joint Disease) 01/2022 - 01/2017
3	Necrosis 10/2018 - 12/2009
3	Musculoskeletal Diseases (Musculoskeletal Disease) 10/2017 - 07/2011
2	Chronic Disease (Chronic Diseases) 01/2022 - 01/2017
2	COVID-19 01/2021 - 01/2021
2	Viremia 01/2020 - 01/2019
2	Neoplasms (Cancer) 10/2018 - 03/2013
2	Human Influenza (Influenza) 03/2017 - 01/2016
2	Disease Progression 01/2012 - 02/2011
2	Rheumatic Diseases (Rheumatism) 02/2011 - 08/2009
2	Asthma (Bronchial Asthma) 07/2008 - 10/2006
1	Psoriatic Arthritis 01/2022
1	Severe Dengue 01/2021
1	Weight Loss (Weight Reduction) 01/2019
1	Peritonitis 10/2018
1	Pneumonia (Pneumonitis) 10/2018
1	Flaviviridae Infections 10/2018
1	Fever (Fevers) 12/2017
1	Zika Virus Infection 11/2017
1	Chronic Obstructive Pulmonary Disease (COPD) 01/2017
1	Arthralgia (Joint Pain) 01/2017
1	Cystitis 08/2015
1	Acute Disease 02/2015
1	Lung Diseases (Lung Disease) 02/2015
1	Pulmonary Eosinophilia (Eosinophilic Pneumonia) 02/2015
1	Osteoarthritis 11/2014

Drug/Important Bio-Agent (IBA)

11	Antiviral Agents (Antivirals)IBA 01/2022 - 09/2007
8	CytokinesIBA 01/2022 - 05/2010
6	InterferonsIBA 01/2022 - 12/2009
6	Pharmaceutical PreparationsIBA 01/2019 - 02/2011
5	Interleukin-6 (Interleukin 6)IBA 01/2022 - 12/2009
5	Complement System Proteins (Complement)IBA 01/2021 - 05/2007
5	bindaritIBA 03/2017 - 08/2009
4	VaccinesIBA 01/2020 - 02/2006
4	Interferon Type IIBA 12/2017 - 01/2007
3	Proteins (Proteins, Gene)FDA Link 01/2018 - 05/2010
3	ChemokinesIBA 10/2017 - 05/2010
3	Monocyte Chemoattractant ProteinsIBA 12/2015 - 08/2009
2	Immunoglobulin G (IgG)IBA 01/2022 - 10/2010
2	Interleukin-17 (Interleukin 17)IBA 01/2022 - 01/2022
2	RNA (Ribonucleic Acid)IBA 01/2020 - 01/2017
2	Messenger RNA (mRNA)IBA 10/2017 - 07/2012
2	Polysaccharides (Glycans)IBA 01/2016 - 08/2015
2	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 10/2011 - 12/2009
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 10/2011 - 02/2011
2	EpitopesIBA 05/2010 - 02/2006
1	Immunoglobulin IsotypesIBA 01/2022
1	AntibodiesIBA 01/2022
1	Interleukin-22 (IL-22)IBA 01/2022
1	Interleukin-23 (Interleukin 23)IBA 01/2022
1	interleukin-21 (interleukin 21)IBA 01/2022
1	Complement Factor B (Factor B)IBA 01/2021
1	Complement Factor H (Factor H)IBA 01/2021
1	DNA (Deoxyribonucleic Acid)IBA 01/2021
1	COVID-19 VaccinesIBA 01/2021
1	Inosine Monophosphate (IMP)IBA 01/2020
1	Liposomes (Liposome)IBA 01/2020
1	Pathogen-Associated Molecular Pattern MoleculesIBA 06/2019
1	Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link 01/2019
1	Interleukin-1 Receptors (Interleukin 1 Receptor)IBA 01/2019
1	LipopolysaccharidesIBA 10/2018
1	RNA-Dependent RNA Polymerase (RNA Dependent RNA Polymerase)IBA 10/2018
1	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 10/2018
1	MethyltransferasesIBA 10/2018
1	AntigensIBA 10/2018
1	CarrageenanIBA 10/2018
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2018
1	Glucose (Dextrose)FDA LinkGeneric 01/2018
1	Biological ProductsIBA 11/2017
1	Interleukin-18 (Interleukin 18)IBA 10/2017
1	InflammasomesIBA 10/2017
1	N- (1,2,3,5,6,7- hexahydro- S- indacen- 4- ylcarbamoyl)- 4- (2- hydroxy- 2- propanyl)- 2- furansulfonamideIBA 10/2017
1	LigandsIBA 10/2017
1	Interleukin-8 (Interleukin 8)IBA 03/2017
1	Granzymes (Granzyme)IBA 01/2017
1	Chemokine CCL5IBA 01/2017
1	Explosive Agents (Explosives)IBA 01/2017
1	MicroRNAs (MicroRNA)IBA 01/2016
1	Glycoproteins (Glycoprotein)IBA 01/2016
1	Collectins (Collectin)IBA 12/2015
1	Intravenous Immunoglobulins (IVIG)FDA Link 11/2015
1	Fc Receptors (Fc Receptor)IBA 11/2015
1	GlycosaminoglycansIBA 08/2015
1	Pentosan Sulfuric Polyester (Pentosan Polysulfate)FDA Link 08/2015
1	Proteoglycans (Proteoglycan)IBA 08/2015
1	Formaldehyde (Formol)FDA Link 02/2015
1	Interleukin-5 (Interleukin 5)IBA 02/2015
1	PTX3 proteinIBA 02/2015
1	Chemokine CCL17IBA 02/2015
1	Cell Surface ReceptorsIBA 10/2013

Therapy/Procedure

7	Therapeutics 01/2021 - 02/2011